Conv. Plasma
Nigella Sativa

All bamlanivimab/etesevimab..
Meta analysis
study COVID-19 treatment researchBamlanivimab/etesevimabBamlaniv../e.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 75% Improvement Relative Risk Hospitalization 65% Bamlanivimab/e..  Alam et al.  EARLY TREATMENT Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19? Retrospective 246 patients in the USA (November 2020 - January 2021) Lower mortality with bamlanivimab/etesevimab (p=0.026) Alam et al., Cureus, May 2021 Favors bamlanivimab/e.. Favors control

Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study

Alam et al., Cureus, doi:10.7759/cureus.14933
May 2021  
  Source   PDF   All   Meta
20th treatment shown to reduce risk in May 2021
*, now known with p = 0.00039 from 19 studies, recognized in 4 countries. Efficacy is variant dependent.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 246 nursing home patients showing lower mortality with early bamlanivimab treatment.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron Haars, Liu, Pochtovyi, Sheward, VanBlargan.
risk of death, 75.0% lower, OR 0.25, p = 0.03, treatment 160, control 86, RR approximated with OR.
risk of hospitalization, 65.0% lower, OR 0.35, p = 0.08, treatment 160, control 86, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alam et al., 10 May 2021, retrospective, USA, peer-reviewed, mean age 82.4, 9 authors, study period 15 November, 2020 - 31 January, 2021. Contact:
This PaperBamlaniv../e..All
Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
Mohammud M Alam, Saborny Mahmud, Sandeep Aggarwal, Sawsan Fathma, Naim Al Mahi, Mohammed S Shibli, Siddiqi M Haque, Sharothy Mahmud, Ziauddin Ahmed
Cureus, doi:10.7759/cureus.14933
Importance Coronavirus disease 2019 (COVID-19) outbreaks are frequent occurrences in nursing homes and long-term care facilities (LTCFs), resulting in subsequent hospitalization and death. Rationale Virus-neutralizing monoclonal antibodies demonstrate a significant decrease in both viral load and hospital transfer rate among patients with mild-to-moderate COVID-19 infection. Objective To assess the clinical outcomes of COVID-19 patients with mild-to-moderate symptoms in LTCFs who received LY-CoV555 as compared to those who did not receive this treatment. Design Retrospective case-control study and logistic regression analysis. Setting LTCFs in New York. Participants Two-hundred forty-six (246) LTCF patients diagnosed with mild-to-moderate COVID-19 infection with positive COVID-19 polymerase chain reaction (PCR) from November 15, 2020, to January 31, 2021. Methods Two-hundred forty-six (246) COVID-19 patients were identified from electronic medical records, out of which 160 cases were exposed to LY-CoV555 treatment (700 mg single dose, intravenous infusion). Eightysix (86) patients were unexposed controls who did not receive monoclonal antibodies, LY-CoV555. Outcome We assessed the odds of death and hospitalization of exposed cases as compared to unexposed controls. Using logistic regression analysis, we also assessed the risk factors associated with these outcomes in the entire sample population.
Additional Information Disclosures Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Ahmad, Alam, Saadi, Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 patients: experience from case series of 54 patients in long-term care facilities, MedRxiv, doi:10.1101/2020.05.18.20066902?utm_medium=email&utm_source=transaction
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191?utm_medium=email&utm_source=transaction
Alam, Mahmud, Rahman, Simpson, Aggarwal et al., Clinical outcomes of early treatment with doxycycline for 89 high-risk COVID-19 patients in long-term care facilities in New York, Cureus, doi:10.7759/cureus.9658?utm_medium=email&utm_source=transaction
Anderson, Rouphael, Widge, Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults, N Engl J Med, doi:10.1056/NEJMoa2028436?utm_medium=email&utm_source=transaction
Borba, Val, Sampaio, Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.8857?utm_medium=email&utm_source=transaction
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2029849?utm_medium=email&utm_source=transaction
Conti, Ronconi, Caraffa, Gallenga, Ross et al., Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COV-19 or SARS-CoV-2): antiinflammatory strategies, J Biol Regul Homeost Agents, doi:10.23812/CONTI-E?utm_medium=email&utm_source=transaction
Dagan, Barda, Kepten, BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting, N Engl J Med, doi:10.1056/NEJMoa2101765?utm_medium=email&utm_source=transaction
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2004168117?utm_medium=email&utm_source=transaction
Fauci, Lane, Redfield, Covid-19 -navigating the uncharted, N Engl J Med, doi:10.1056/NEJMe2002387?utm_medium=email&utm_source=transaction
Hansen, Baum, Pascal, Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail, Science, doi:10.1126/science.abd0827?utm_medium=email&utm_source=transaction
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052?utm_medium=email&utm_source=transaction
Joyner, Carter, Senefeld, Convalescent plasma antibody levels and the risk of death from Covid-19, N Engl J Med, doi:10.1056/NEJMoa2031893?utm_medium=email&utm_source=transaction
Levi, Thachil, Iba, Levy, Coagulation abnormalities and thrombosis in patients with COVID-19, Lancet Haematol, doi:10.1016/S2352-3026(20)30145-9?utm_medium=email&utm_source=transaction
Li, Zhang, Hu, Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2020.10044?utm_medium=email&utm_source=transaction
Marovich, Mascola, Cohen, Monoclonal antibodies for prevention and treatment of COVID-19, JAMA, doi:10.1001/jama.2020.10245?utm_medium=email&utm_source=transaction
Pinto, Park, Beltramello, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, doi:10.1038/s41586-020-2349-y?utm_medium=email&utm_source=transaction
Regeneron, None
Rogers, Shehadeh, Mylona, Convalescent plasma for patients with severe COVID-19: a matched cohort study, Clin Infect Dis, doi:10.1093/cid/ciaa1548?utm_medium=email&utm_source=transaction
Rosas, Bräu, Waters, Tocilizumab in hospitalized patients with COVID-19 pneumonia, MedRxiv, doi:10.1101/2020.08.27.20183442?utm_medium=email&utm_source=transaction
Shang, Zhao, Hu, Du, Cao, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet, doi:10.1016/S0140-6736(20)30361-5?utm_medium=email&utm_source=transaction
Spinner, Gottlieb, Criner, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial, JAMA, doi:10.1001/jama.2020.16349?utm_medium=email&utm_source=transaction
Tang, Li, Wang, Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, doi:10.1111/jth.14768?utm_medium=email&utm_source=transaction
Vabret, Britton, Gruber, Immunology of COVID-19: current state of the science, Immunity, doi:10.1016/j.immuni.2020.05.002?utm_medium=email&utm_source=transaction
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002?utm_medium=email&utm_source=transaction
Zhou, Fu, Zheng, Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Natl Sci Rev, doi:10.1093/nsr/nwaa041?utm_medium=email&utm_source=transaction
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop